BenchSci

AI-driven platform for preclinical research

Toronto, Ontario, Canada

About BenchSci

BenchSci operates in the biotechnology sector, specializing in preclinical research and development. The company uses artificial intelligence and machine learning to create a detailed map of disease biology, which helps scientists understand existing research and improve their R&D efficiency. Its main product, ASCEND, is a platform that extracts evidence from various data sources to assist scientists in hypothesis generation and risk identification. BenchSci aims to enhance research capabilities and reduce risks in preclinical studies.

Toronto, CanadaHeadquarters

2015Year Founded

$156.6MTotal Funding

SERIES_DCompany Stage

AI & Machine Learning, BiotechnologyIndustries

201-500Employees

Benefits

Remote-first culture

Equity options

15 days vacation + additional day every year

Unlimited flex time

Comprehensive health & dental benefits

Psychotherapist services

Annual Learning & Development budget

Home office set-up budget

Wellness, lifestyle & productivity spending account

Risks

17% workforce reduction may impact morale and innovation at BenchSci.

Heavy reliance on external funding poses financial risks if future rounds falter.

Rapid team expansion could lead to integration challenges and inefficiencies.

Differentiation

BenchSci's ASCEND platform uses AI to map disease biology for drug discovery.

ASCEND helps scientists identify risks and generate hypotheses in preclinical R&D.

BenchSci's AI Reagent Selector improves reagent selection efficiency in drug development.

Upsides

$95M Series D funding boosts BenchSci's AI platform development and market reach.

Generative AI integration enhances ASCEND's predictive capabilities for hypothesis generation.

Recognition as a Best Workplace for Inclusion attracts top talent and fosters innovation.

Funding

Total raised$156.59 M

Latest valuation$475.00 M

StageSERIES_D

SERIES D

4/30/2023

$70

$475.00 M

SERIES C

12/31/2021

$46

$315.00 M

SERIES B

1/31/2021

$10

$50.00 M

SERIES A

5/31/2019

$25.50 M

GRANT

12/31/2014

N/A